Application of betulinic acid derivatives in preparation of drugs inhibiting T cell differentiation

A technology of betulinic acid and cell differentiation, applied in the application field of medicine

Active Publication Date: 2015-02-11
EAST CHINA NORMAL UNIV
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although MOG accounts for only 0.01-0.05% of myelin sheath proteins in the central nervous system, it is highly immunogenic due to its presence in the outermost layer of oligodendrocytes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of betulinic acid derivatives in preparation of drugs inhibiting T cell differentiation
  • Application of betulinic acid derivatives in preparation of drugs inhibiting T cell differentiation
  • Application of betulinic acid derivatives in preparation of drugs inhibiting T cell differentiation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1: drug screening

[0037] The full name of MTT is 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenyltetrazolium romide, and the Chinese chemical name is 3-(4,5-dimethylthiazol-2)-2,5- Diphenyltetrazolium bromide, trade name thiazolium blue, is a yellow dye. MTT colorimetry is a method for detecting cell survival and growth. Its detection principle is that succinate dehydrogenase in the mitochondria of living cells can reduce exogenous MTT to water-insoluble blue-purple crystal formazan (Formazan) and deposit it. in cells.

[0038] method:

[0039] (1) will 2.5×10 5 100 μl of spleen lymphocytes were placed in a 96-well plate, and three replicate wells were set up for each group.

[0040] (2) Add MOG in vitro 35-55 The final concentration of stimulation (blank control) was 20 μg / ml, and drugs of different concentrations were added.

[0041] (3) The cells were cultured in a 37°C, 5% CO2 incubator for 72 hours.

[0042] (4) Add 20 μl MTS to each well, and pla...

Embodiment 2

[0047] Example 2: Administration of XJ479 in CIA can alleviate the severity of its onset

[0048] Principle: Administration of betulinic acid derivative XJ479 represented by formula (1) in vivo to alleviate the onset of CIA (inflammatory response, cartilage and bone damage)

[0049] Methods: Male DBA / 1J mice (6-8 weeks) were injected with fully emulsified CII to induce CIA model. Three groups were set up, with 8 mice in each group, and all mice except the normal group were subcutaneously injected with antigen CII at a dose of 100 μg / mouse. The day of immunization was day 0, and the second immunization was performed after day 21. XJ479 (20 mg / kg / day, dissolved in 50 μl DMSO) was administered intraperitoneally on day 23, and the corresponding control group was injected with an equivalent amount of 50 μl DMSO. And the mice were observed from the 22nd day, and the severity of the disease and the degree of joint swelling of the mice were recorded. After the mice reached the peak ...

Embodiment 3

[0051] Example 3: Administration of XJ479 in EAE can alleviate the severity of its onset

[0052] Principle: Administration of betulinic acid derivative XJ479 represented by formula (1) in vivo to alleviate the onset of EAE (infiltration of inflammatory cells in the central nervous system and relief of inflammatory response)

[0053]Method: Prepare 1) complete Freund's adjuvant, add heat-inactivated Mycobacterium tuberculosis (H37RA) to the incomplete Freund's adjuvant to make the final concentration 5 mg / ml, and mix well. 2) MOG polypeptide: Dissolve MOG with 1×PBS (PH7.2) to make a final concentration of 3 mg / ml. 3) Pertussis toxin (PTX): Dissolve PTX with 1×PBS (PH7.2)+50mM NaCl to prepare the final concentration. Then emulsify the antigen, put complete Freund's adjuvant into an emulsification tube, and put a three-way valve on it. Put an equal volume of dissolved MOG into another emulsification tube, connect it with complete Freund's adjuvant with a three-way valve after...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of betulinic acid derivatives in preparation of drugs inhibiting T cell differentiation, relieving inflammation and alleviating bone injury. The BA and its derivatives involved in the invention can inhibit T cell differentiation, has an anti-inflammatory effect in autoimmune diseases so as to relieve inflammation, and can be used for preparation of drugs treating autoimmune diseases like rheumatoid arthritis and experimental encephalomyelitis, etc.

Description

technical field [0001] The invention belongs to the technical field of drug application, and in particular relates to the application of betulinic acid derivatives in the preparation of drugs for inhibiting T cell differentiation. Background technique [0002] Autoimmune disease is a disease caused by the body's immune response to self-antigens and damage to its own tissues. According to the scope of dysfunction, it can be divided into organ-specific autoimmune diseases and systemic autoimmune diseases. Organ-specific autoimmune diseases include multiple sclerosis, insulin-dependent diabetes, etc., and its dysfunction is limited to a certain organ; Systemic autoimmune diseases, including rheumatoid arthritis, systemic lupus, etc., can eventually cause damage to multiple organs. [0003] Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease. Its main manifestations are inflammatory synovitis, which causes joint redness, swelling, pain and stiffness caused by in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61P29/00A61P19/08A61P19/02A61P37/02
CPCA61K31/58
Inventor 罗剑李珍荆吉仇文卫刘明耀陈华青汤杰杨帆
Owner EAST CHINA NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap